MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pfizer (NY:PFE)

29.21 +0.84 (+2.96%)
Official Closing Price Updated: 4:10 PM EDT, Oct 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Most active S&P500 stocks in Wednesday's session ↗
Via Chartmill
Exploring the top movers within the S&P500 index during today's session. ↗
Via Chartmill
News headline image
Forget Treasury Bonds: This 6%-Yielding Pharma Stock Pays You to Wait for Its Pipeline ↗
A reliable payout, a growing cancer treatment lineup, and improving guidance make this drugmaker worth a second look right now. 
Via The Motley Fool
Topics Bonds
News headline image
Pfizer Showcases Clinical Advancements Across Infectious Diseases at IDWeek 2026
From Pfizer Inc.
Via Business Wire
News headline image
Branded Pharmaceuticals Stocks Q2 In Review: Zoetis (NYSE:ZTS) Vs Peers
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q2. Today, we are looking a... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
Johnson & Johnson vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? ↗
Johnson & Johnson trades at a higher valuation with growing sales, while Pfizer's dividend yield is near 6% as patents expire from 2026 through 2030. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Better Invesco Healthcare ETF: PJP Targeting Pharmaceuticals vs. RSPH's Broader Sector Lens ↗
PJP's one-year return beats RSPH's, but RSPH offers broader diversification across 61 healthcare holdings at a lower expense ratio. 
Via The Motley Fool
Topics ETFs
News headline image
How Much Would You Need to Invest in These 5 Pharma Stocks to Earn $1,000 a Month in Dividends? ↗
You'll need to generate $12,000 a year in dividends to average $1k per month from Amgen, Pfizer, J&J, AbbVie, and Bristol Myers Squibb. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Better Pharma ETF: iShares IHE vs. State Street XPH ↗
IHE concentrates 23.6% in Eli Lilly and delivers 1.4% yield, while XPH spreads risk across 62 holdings with a lower 0.35% expense ratio. 
Via The Motley Fool
Topics ETFs
News headline image
Alnylam vs. Ionis: Here's the Better Bad-News Buy ↗
The sell-offs for both of these beaten-down biotech stocks appear to be overdone. 
Via The Motley Fool
News headline image
Bristol Myers Squibb vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? ↗
Both face patent cliffs and regulatory headwinds, but their balance sheets and cash generation tell starkly different stories. 
Via The Motley Fool
Topics Intellectual Property
News headline image
2 Growth Stocks to Buy in October ↗
Grail and Veeva Systems could be well insulated from near-term headwinds. 
Via The Motley Fool
News headline image
Pfizer Trades Under 10 Times Forward Earnings With a Yield Near 6%. Here's What History Says Happens Next. ↗
Pfizer is deeply unloved, and for good reason, but don't count this drug maker out just yet. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Avident Health and Unite for HER Awarded Quality Improvement Grant from Pfizer and the National Comprehensive Cancer Network® (NCCN®) to Support Metastatic Breast Cancer Patients
October 8, 2026 -- Initiative leverages the MyNavigator™ digital care coordination platform to translate NCCN Guidelines® into actionable home-based education, expand access to integrative oncology... 
Via 24-7 Press Release
News headline image
Pfizer Stock: Buy, Sell, or Hold? ↗
The company is entering what could be a particularly challenging period. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Pfizer’s TUKYSA Regimen Receives FDA Approval as Front-Line Maintenance Treatment for HER2+ Metastatic Breast Cancer
From Pfizer Inc.
Via Business Wire
News headline image
D-Wave Quantum vs. Rigetti Computing: Which Cutting Edge Quantum Stock Is a Better Buy in 2026? ↗
D-Wave is growing revenue at nearly 180% while Rigetti trades at a lower valuation, but both burn cash heavily and face unproven commercial roadmaps. 
Via The Motley Fool
Topics Supply Chain
News headline image
Warren Buffett's Favorite Valuation Indicator Blew Past the Level He Warned Was "Playing With Fire." Here Are 3 Stocks Still Cheap Enough to Buy. ↗
Buffett thinks many stocks are too hot to touch right now, but these three aren't. 
Via The Motley Fool
Topics Artificial Intelligence Energy
News headline image
1 Healthcare Stock with Competitive Advantages and 2 We Find Risky
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from eleva... 
Via StockStory
News headline image
3 of the Best Dividend Stocks to Buy in October 2026 ↗
A couple of the stocks on this list pay more than 6% in dividends. 
Via The Motley Fool
Topics Economy Intellectual Property
News headline image
Pfizer Declares Fourth-Quarter 2026 Dividend
From Pfizer Inc.
Via Business Wire
News headline image
2 Unpopular Stocks That Should Get More Attention and 1 Facing Challenges
Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad t... 
Via StockStory
News headline image
Eli Lilly Has Been a Growth Beast, but This Is the Riskiest Part About Its Stock ↗
The healthcare stock's elevated valuation bakes in high expectations, leaving little room for error. 
Via The Motley Fool
News headline image
Why Pfizer Might Be the Most Underrated Dividend Stock to Buy Right Now ↗
Many dividend investors may be overlooking Pfizer's stock, and that could be a costly mistake. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Vaxcyte Catapults After Going Toe-To-Toe With Pfizer, Merck In Vaccine Study ↗
Vaxcyte stock catapulted Monday after its pneumococcal vaccine proved it's not inferior to shots from Pfizer and Merck. 
Via Investor's Business Daily
News headline image
Eli Lilly vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? ↗
Eli Lilly is dominating the GLP-1 market with nearly 50% revenue growth and a newly approved oral obesity pill. Pfizer is rebuilding its pipeline with obesity drug ambitions and a committed dividend... 
Via The Motley Fool
Topics Intellectual Property
News headline image
Got $10,000 to Invest in October? These Stocks Could Generate Over $634 in Annual Income. ↗
Put your money to work generating dividend income with these stocks. 
Via The Motley Fool
News headline image
Better High-Yield Dividend Stock: Pfizer or Novo Nordisk? ↗
Novo Nordisk covers its dividend, and Pfizer doesn't, but investors appear increasingly worried about Novo's future. 
Via The Motley Fool
News headline image
Here's Exactly Why I'm Not Afraid of Pfizer's 6% Dividend Yield ↗
The crowd is looking at the next couple of years. It should be looking five years into the future. 
Via The Motley Fool
Topics Intellectual Property
News headline image
3 Dirt Cheap Dividend Stocks Worth Buying in October ↗
There are blazing deals for some of the top healthcare stocks -- companies with proven track records and dividend yields as high as 6%. 
Via The Motley Fool
Topics Intellectual Property
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story